Pfizer (PFE) : Oakwood Capital Managementca reduced its stake in Pfizer by 1.91% during the most recent quarter end. The investment management company now holds a total of 158,109 shares of Pfizer which is valued at $5,826,317 after selling 3,075 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Pfizer makes up approximately 1.47% of Oakwood Capital Managementca’s portfolio.
Other Hedge Funds, Including , Headinvest reduced its stake in PFE by selling 500 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 27,566 shares of PFE which is valued at $1,015,807. Pfizer makes up approx 0.38% of Headinvest’s portfolio.Hoertkorn Richard Charles reduced its stake in PFE by selling 2,200 shares or 3.2% in the most recent quarter. The Hedge Fund company now holds 66,485 shares of PFE which is valued at $2,442,659. Pfizer makes up approx 1.86% of Hoertkorn Richard Charles’s portfolio.Bollard Group boosted its stake in PFE in the latest quarter, The investment management firm added 438 additional shares and now holds a total of 65,399 shares of Pfizer which is valued at $2,402,759. Pfizer makes up approx 0.16% of Bollard Group’s portfolio.Loring Wolcott Coolidge Fiduciary Advisors Llpma boosted its stake in PFE in the latest quarter, The investment management firm added 10,797 additional shares and now holds a total of 78,856 shares of Pfizer which is valued at $2,863,261. Pfizer makes up approx 0.06% of Loring Wolcott Coolidge Fiduciary Advisors Llpma’s portfolio.
Pfizer opened for trading at $36.68 and hit $36.95 on the upside on Friday, eventually ending the session at $36.89, with a gain of 0.60% or 0.22 points. The heightened volatility saw the trading volume jump to 2,15,13,828 shares. Company has a market cap of $223,732 M.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.